Transarterial Chemoembolization (TACE) Plus Sorafenib Versus TACE for Advanced Hepatocellular Carcinoma

Inclusion Criteria: * Male or female patients \> 18 years and \<=70 years of age. * at least 2 radiologic imaging showing characteristic features of hepatocellular carcinoma or cytologic/histologic evidence. * tumor in liver and radiologically definable vascular invasion or extrahepatic metastasis. * Criteria of liver function: Child A-B level, serum bilirubin ≤ 1.5 times the upper limit of normal value,alanine aminotransferase and aspartate aminotransferase ≤ 2 times the upper limit of normal value. * No dysfunction in major organs; Blood routine, kidney function, cardiac function and lung function are basically normal. * Hb ≥90g/L,white blood cell count ≥3.000 cells/mm³,platelets ≥80.000 cells/mm³ * Patients who can understand this trial and have signed information consent Exclusion Criteria: * Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction,which may affect the treatment of liver cancer. * Patients with other diseases which may affect the treatment mentioned. * Patients with a medical history of other malignant tumors. * Subjects participating in other clinical trials. * liver function:Child C. * no pathological evidence of hepatocellular carcinoma.